Evidence map›Paper›PMID 35655425›Full record

ArticlePsychiatry and clinical neurosciences2022

Changes in psychotropic polypharmacy and high-potency prescription following policy change: Findings from a large scale Japanese claims database.

Masahiro Takeshima, Minori Enomoto, Masaya Ogasawara, Mizuki Kudo, Yu Itoh, Kazuhisa Yoshizawa, Dai Fujiwara, Yoshikazu Takaesu, Kazuo Mishima

Abstract readLetter
In one paragraph

Article in Psychiatry and clinical neurosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Masahiro TakeshimaDepartment of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.ORCID 0000-0003-0614-7524
Minori EnomotoDepartment of Medical Technology, School of Health Sciences, Tokyo University of Technology, Tokyo, Japan.
Masaya OgasawaraDepartment of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
Mizuki KudoDepartment of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
Yu ItohDepartment of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
Kazuhisa YoshizawaDepartment of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
Dai FujiwaraDepartment of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.
Yoshikazu TakaesuDepartment of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.ORCID 0000-0002-9169-3249
Kazuo MishimaDepartment of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan.ORCID 0000-0003-1182-1181

Funding

Japanese Ministry of Health, Labour and Welfare R3-21GC1016
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

PolypharmacyPsychotropic DrugsHumansJapanPolicyPrescriptionsPsychotropic Drugs

Identifiers

PMID35655425
PMCPMC9546399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.